Latest News
CareDx, Inc.
- CareDx Reports AlloSure Kidney Data Showing Nearly Threefold Higher Risk of Adverse Transplant Outcomes
- CareDx links AlloSure Kidney to adverse graft outcomes
- Caredx Announces New Koar Data Linking Elevated Allosure® Kidney To Nearly 3-Fold Higher Risk Of Adverse Graft Outcomes In Patients With Borderline Rejection Or Tcmr At Asn Kidney Week 2026
- CareDx presents kidney transplant monitoring study results By Investing.com
- CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
- Caredx Inc stock hits 52-week high at 72.61 USD By Investing.com
- Price to earnings forward of CareDx, Inc. – HAM:1K9
- CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overva
- CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
- CareDx Inc (CDNA) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 64/100
- CareDx (CDNA) Tumbles 8.68% to $63.79 as Shares Retreat Toward Key Support - Strangle Setup
- CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade)
Headlines from the last 30 days, linking to the original publishers. See all market news →